Novo Nordisk Initiates Share Repurchase Program
Ticker: NONOF · Form: 6-K · Filed: Feb 4, 2025 · CIK: 353278
Sentiment: neutral
Topics: share-repurchase, regulation, capital-return
TL;DR
Novo Nordisk is buying back its own stock under a new program.
AI Summary
Novo Nordisk A/S announced on February 4, 2025, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance with European regulations MAR and Commission Delegated Regulation (EU) 2016/1052.
Why It Matters
This indicates Novo Nordisk is returning capital to shareholders, potentially signaling confidence in its financial health and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a share repurchase program, which is a common corporate action.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant and issuer of the share repurchase program
- February 4, 2025 (date) — Date of the announcement
- November 11, 2024 (date) — Date the share repurchase program was initiated
- Regulation No 596/2014 (regulation) — European regulation governing the share repurchase program
- Commission Delegated Regulation (EU) 2016/1052 (regulation) — European regulation governing the share repurchase program
FAQ
When was the share repurchase program initiated?
The share repurchase program was initiated on November 11, 2024.
What is the announcement date of this filing?
The announcement date is February 4, 2025.
Under which regulations is the share repurchase program being conducted?
The program is being conducted in accordance with Regulation No 596/2014 and Commission Delegated Regulation (EU) 2016/1052.
What is the company's principal executive office address?
The principal executive office is located at Novo Allé 1 DK- 2880, Bagsvaerd Denmark.
Does Novo Nordisk file annual reports under Form 20-F or 40-F?
Novo Nordisk files annual reports under Form 20-F.
Filing Stats: 634 words · 3 min read · ~2 pages · Grade level 9.9 · Accepted 2025-02-04 09:24:46
Filing Documents
- f6k_020425.htm (6-K) — 27KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-25-000599.txt ( ) — 167KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: February 4, 2025 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer